Olea pollen allergy immunotherapy - Laboratorios LETI

Drug Profile

Olea pollen allergy immunotherapy - Laboratorios LETI

Latest Information Update: 04 May 2015

Price : $50

At a glance

  • Originator Laboratorios LETI
  • Class Allergens; Antiallergics; Tree pollen allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Seasonal allergic rhinitis

Most Recent Events

  • 31 Jan 2013 Laboratorios Leti completes the phase III OLEA trial in Seasonal allergic rhinitis in Spain (NCT00831025)
  • 16 Oct 2012 Phase-III development is ongoing in Spain
  • 10 Aug 2011 Laboratorios Leti completes enrolment in its phase III trial for Seasonal allergic rhinitis in Spain (NCT00831025)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top